Shares of Aimmune Therapeutics (NASDAQ:AIMT) have received an average recommendation of “Buy” from the eleven analysts that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $60.13.
Several research firms recently commented on AIMT. BidaskClub upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Credit Suisse Group set a $45.00 price target on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a report on Thursday, January 11th. Zacks Investment Research cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, January 8th. Wedbush restated an “outperform” rating on shares of Aimmune Therapeutics in a report on Monday, February 12th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Aimmune Therapeutics in a report on Tuesday, February 20th.
In other Aimmune Therapeutics news, insider Mary M. Rozenman sold 1,807 shares of Aimmune Therapeutics stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $33.10, for a total value of $59,811.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Douglas T. Sheehy sold 3,523 shares of Aimmune Therapeutics stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $36.52, for a total transaction of $128,659.96. Following the completion of the sale, the insider now owns 32,500 shares of the company’s stock, valued at $1,186,900. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 58,093 shares of company stock valued at $1,858,976 and sold 15,445 shares valued at $552,210. 24.56% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Hamilton Lane Advisors LLC acquired a new stake in Aimmune Therapeutics in the fourth quarter valued at approximately $2,982,000. Virtus Fund Advisers LLC bought a new position in shares of Aimmune Therapeutics in the fourth quarter valued at approximately $391,000. First Republic Investment Management Inc. bought a new position in shares of Aimmune Therapeutics in the fourth quarter valued at approximately $202,000. MYDA Advisors LLC bought a new position in shares of Aimmune Therapeutics in the fourth quarter valued at approximately $378,000. Finally, Virtu Financial LLC bought a new position in shares of Aimmune Therapeutics in the fourth quarter valued at approximately $239,000. Hedge funds and other institutional investors own 65.95% of the company’s stock.
Shares of AIMT stock traded up $0.30 during trading on Monday, hitting $31.63. 268,670 shares of the company were exchanged, compared to its average volume of 738,075. The stock has a market cap of $1,817.90, a P/E ratio of -12.12 and a beta of -0.38. Aimmune Therapeutics has a twelve month low of $15.97 and a twelve month high of $42.00.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.09). analysts predict that Aimmune Therapeutics will post -2.72 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Aimmune Therapeutics (AIMT) Receives $60.13 Consensus Target Price from Analysts” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/21/aimmune-therapeutics-aimt-receives-60-13-consensus-target-price-from-analysts.html.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.